Neurosense TherapeuticsNRSN
13F holders, Q1 2026 (March 31)13holders
3new positions
3sold out
$0.75avg. 13F price*
At the end of Q1 2026, 13 institutions reported holding Neurosense Therapeutics Ltd. (NRSN) in their 13F filings, unchanged from Q4 2025. 3 opened new positions and 3 sold out. The largest holders were Yorkville Advisors Global, LP ($59K), Independent Advisor Alliance ($38K) and UBS Group AG ($37K).
- Company
- Neurosense Therapeutics Ltd.
- CUSIP
- M74240108
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $75K |
| Exits | 3 | $42K |
All 13F filers, Q4 2025 → Q1 2026: 118,045 shares bought and 84,469 shares sold, net +33,576 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 13 holders
| Yorkville Advisors Global, LP | 0.04% | Reduce -22.0% | 78,000 | $59K |
| Independent Advisor Alliance | 0.00% | New | 50,000 | $38K |
| UBS Group AG | 0.00% | Add +59.0% | 49,096 | $37K |
| Two Sigma Investments, LP | 0.00% | Reduce -13.8% | 44,445 | $34K |
| Meitav Investment House Ltd. | 0.00% | No change | 40,000 | $30K |
| Jane Street Group, LLC | 0.00% | New | 28,670 | $22K |
| Commonwealth Equity Services, LLC | 0.00% | No change | 22,775 | $17K |
| PNC Financial Services Group, Inc. | 0.00% | New | 21,150 | $16K |
| Pathstone Holdings, LLC | 0.00% | No change | 16,528 | $12K |
| Geode Capital Management, LLC | 0.00% | No change | 15,870 | $12K |
| Creative Planning | 0.00% | No change | 11,911 | $9K |
| Jones Financial Companies LLLP | 0.00% | No change | 1,000 | $731 |
| SBI Securities Co., Ltd. | 0.00% | Reduce -81.8% | 265 | $200 |
"% of holder's portfolio" is NRSN's weight in each manager's 13F, not the share of Neurosense Therapeutics Ltd. the manager owns.